{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:33:18Z","timestamp":1771666398988,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T00:00:00Z","timestamp":1131494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T00:00:00Z","timestamp":1131494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Studies on autoantibody production in patients treated with tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors reported contradictory results. We investigated in a prospective study the efficacy of a treatment with human monoclonal anti-TNF-\u03b1 antibody (adalimumab) in patients with rheumatoid arthritis (RA) and we evaluated the relationship between treatment efficacy and the incidence and titers of disease-associated and non-organ-specific autoantibodies. Fifty-seven patients with RA not responsive to methotrexate and treated with adalimumab were enrolled. Antinuclear, anti-double-stranded(ds)DNA, anti-extractable nuclear antigens, anti-cardiolipin (aCL), anti-\u03b2<jats:sub>2<\/jats:sub> glycoprotein I (anti-\u03b2<jats:sub>2<\/jats:sub>GPI) autoantibodies, rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) autoantibodies were investigated at baseline and after 6 and 12 months of follow-up. Comparable parameters were evaluated in a further 55 patients treated with methotrexate only. Treatment with adalimumab induced a significant decrease in RF and anti-CCP serum levels, and the decrease in antibody titers correlated with the clinical response to the therapy. A significant induction of antinuclear autoantibodies (ANA) and IgG\/IgM anti-dsDNA autoantibodies were also found in 28% and 14.6% patients, respectively, whereas aCL and anti-\u03b2<jats:sub>2<\/jats:sub>GPI autoantibodies were not detected in significant quantities. No association between ANA, anti-dsDNA, aCL and anti-\u03b2<jats:sub>2<\/jats:sub>GPI autoantibodies and clinical manifestations was found. Clinical efficacy of adalimumab is associated with the decrease in RF and anti-CCP serum levels that was detected after 24 weeks and remained stable until the 48th week of treatment. Antinuclear and anti-dsDNA autoantibodies, but not anti-phospholipid autoantibodies, can be induced by adalimumab but to a lower extent than in studies with other anti-TNF blocking agents.<\/jats:p>","DOI":"10.1186\/ar1851","type":"journal-article","created":{"date-parts":[[2005,11,10]],"date-time":"2005-11-10T20:35:01Z","timestamp":1131654901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study"],"prefix":"10.1186","volume":"8","author":[{"given":"Fabiola","family":"Atzeni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"Dell' Acqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"de Portu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germana","family":"Cecchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Cruini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,11,9]]},"reference":[{"key":"1731_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese C, Wasko MC, Moreland LW, Weaver AW, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056\/NEJM200011303432201.","journal-title":"N Engl J Med"},{"key":"1731_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, et al: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 344: 1105-1110. 10.1016\/S0140-6736(94)90628-9.","journal-title":"Lancet"},{"key":"1731_CR3","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000, 343: 1594-1602. 10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"key":"1731_CR4","first-page":"333","volume":"6","author":"L Moreland","year":"2004","unstructured":"Moreland L: Adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2004, 6: 333-334.","journal-title":"Curr Rheumatol Rep"},{"key":"1731_CR5","doi-asserted-by":"publisher","first-page":"ii67","DOI":"10.1136\/ard.61.suppl_2.ii67","volume":"61 Suppl 2","author":"EW St Clair","year":"2002","unstructured":"St Clair EW: Infliximab treatment for rheumatic disease: clinical and radiological efficacy. Ann Rheum Dis. 2002, 61 Suppl 2: ii67-ii69.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR6","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard.2003.014647","volume":"63","author":"C Alessandri","year":"2004","unstructured":"Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF\u03b1 therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004, 63: 1218-1221. 10.1136\/ard.2003.014647.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR7","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","volume":"43","author":"PJ Charles","year":"2000","unstructured":"Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor-\u03b1: findings in open-label and randomised placebo-controlled trials. Arthritis Rheum. 2000, 43: 2383-2390. 10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4.","journal-title":"Arthritis Rheum"},{"key":"1731_CR8","doi-asserted-by":"publisher","first-page":"R264","DOI":"10.1186\/ar1173","volume":"6","author":"F Bobbio-Pallavicini","year":"2004","unstructured":"Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C: Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004, 6: R264-R272. 10.1186\/ar1173.","journal-title":"Arthritis Res Ther"},{"key":"1731_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/ard.2004.024182","volume":"64","author":"C Eriksson","year":"2005","unstructured":"Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S: Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF\u03b1. Ann Rheum Dis. 2005, 64: 403-407. 10.1136\/ard.2004.024182.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/ard.2004.023523","volume":"64","author":"L De Rycke","year":"2005","unstructured":"De Rycke L, Verhelst X, Kruithof E, Van den Bosh F, Hoffman IE, Veys EM, De Keyser F: Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 299-302. 10.1136\/ard.2004.023523.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00296-004-0571-9","volume":"26","author":"P Caramaschi","year":"2005","unstructured":"Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM: Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int. 2005, 26: 58-62. 10.1007\/s00296-004-0571-9.","journal-title":"Rheumatol Int"},{"key":"1731_CR12","first-page":"s534","volume":"46","author":"M Antivalle","year":"2002","unstructured":"Antivalle M, Marazza MG, Randisi G, Sarzi-Puttini P, Dell'Acqua D, Carrabba M: Longterm treatment of rheumatoid arthritis with infliximab: efficacy, side effects and autoantibodies induction [abstract]. Arthritis Rheum. 2002, 46: s534-","journal-title":"Arthritis Rheum"},{"key":"1731_CR13","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/art.10876","volume":"48","author":"L De Rycke","year":"2003","unstructured":"De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F: Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003, 48: 1015-1023. 10.1002\/art.10876.","journal-title":"Arthritis Rheum"},{"key":"1731_CR14","first-page":"2557","volume":"30","author":"M Louis","year":"2003","unstructured":"Louis M, Rauch J, Armstrong M, Fitzcharles MA: Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol. 2003, 30: 2557-2562.","journal-title":"J Rheumatol"},{"key":"1731_CR15","first-page":"756","volume":"22","author":"Y Allanore","year":"2004","unstructured":"Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A: Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004, 22: 756-758.","journal-title":"Clin Exp Rheumatol"},{"key":"1731_CR16","doi-asserted-by":"publisher","first-page":"R535","DOI":"10.1186\/ar1440","volume":"6","author":"C Ferraro-Peyret","year":"2004","unstructured":"Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N: Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004, 6: R535-R543. 10.1186\/ar1440.","journal-title":"Arthritis Res Ther"},{"key":"1731_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/00002281-200305000-00014","volume":"15","author":"M Ziolkowska","year":"2003","unstructured":"Ziolkowska M, Maslinski W: Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis. Curr Opin Rheumatol. 2003, 15: 267-273. 10.1097\/00002281-200305000-00014.","journal-title":"Curr Opin Rheumatol"},{"key":"1731_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","volume":"22","author":"M Debandt","year":"2003","unstructured":"Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O: Anti-TNF\u03b1-induced systemic lupus erythematosus. Clin Rheumatol. 2003, 22: 56-61. 10.1007\/s10067-002-0654-5.","journal-title":"Clin Rheumatol"},{"key":"1731_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/ard.61.4.358","volume":"61","author":"G Ferraccioli","year":"2002","unstructured":"Ferraccioli G, Mecchia F, Di Poi E, Fabris M: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional comnination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002, 61: 358-361. 10.1136\/ard.61.4.358.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/ard.2003.018093","volume":"63","author":"T Jonsdottir","year":"2004","unstructured":"Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannenmark S, Klareskog L, van Vollenhoven RF: Treatment with anti-TNF\u03b1 antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004, 63: 1075-1078. 10.1136\/ard.2003.018093.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002\/art.10697.","journal-title":"Arthritis Rheum"},{"key":"1731_CR22","first-page":"s63","volume-title":"Ann Rheum Dis","author":"GR Burmester","year":"2004","unstructured":"Burmester GR, Monteagudo Saez I, Malaise M, Canas da Silva J, Webber DG, Kupper H: Efficacy and safety of Adalimumab (HUMIRA) in European Clinical Practice: The ReAct trial. Ann Rheum Dis. 2004, s63-[abstract]"},{"key":"1731_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324.","journal-title":"Arthritis Rheum"},{"key":"1731_CR24","first-page":"579","volume":"20","author":"DM van der Heijde","year":"1993","unstructured":"van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993, 20: 579-581.","journal-title":"J Rheumatol"},{"key":"1731_CR25","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, et al: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38: 727-735.","journal-title":"Arthritis Rheum"},{"key":"1731_CR26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/ard.61.7.608","volume":"61","author":"T Avcin","year":"2002","unstructured":"Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, Porenta-Besic V, Cecchini G, Borghi MO, Meroni PL: Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis. 2002, 61: 608-611. 10.1136\/ard.61.7.608.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/jaut.1999.0298","volume":"13","author":"PM Bayer","year":"1999","unstructured":"Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gilburd B, Heide KG, Hoier-Madsen M, Meroni PL, Monier JC, et al: Multicenter evaluation study on a new HEp2 ANA screening enzyme immune assay. J Autoimmun. 1999, 13: 89-93. 10.1006\/jaut.1999.0298.","journal-title":"J Autoimmun"},{"key":"1731_CR28","first-page":"449","volume-title":"Autoantigens, Autoantibodies, Autoimmunity","author":"MJ Fritzler","year":"2004","unstructured":"Fritzler MJ: New technologies in the detection of autoantibodies evaluation of addressable laser bead immunoassays (ALBIA). Autoantigens, Autoantibodies, Autoimmunity. Edited by: Conrad K, Bachmann MP, Chan EKL, Fritzler MJ, Humbel RL, Sack U, Shoenfeld Y. 2004, Berlin: Pabst Science Publishers, 4: 449-462."},{"key":"1731_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/08916930400022616","volume":"38","author":"P Riboldi","year":"2005","unstructured":"Riboldi P, Gerosa M, Moroni G, Radice A, Sinico A, Tincani A, Meroni PL: Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity. 2005, 38: 39-45.","journal-title":"Autoimmunity"},{"key":"1731_CR30","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1616089","volume":"86","author":"A Tincani","year":"2001","unstructured":"Tincani A, Allegri F, Sanmarco M, Cinquini M, Taglietti M, Balestrieri G, Koike T, Ichikawa K, Meroni P, Boffa MC: Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations \u2013 a cooperative project of the European Antiphospholipid Forum. Thromb Haemost. 2001, 86: 575-583.","journal-title":"Thromb Haemost"},{"key":"1731_CR31","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/art.10167","volume":"46","author":"M Bukhari","year":"2002","unstructured":"Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. 2002, 46: 906-912. 10.1002\/art.10167.","journal-title":"Arthritis Rheum"},{"key":"1731_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3","volume":"43","author":"GA Schellekens","year":"2000","unstructured":"Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ: The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000, 43: 155-163. 10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.","journal-title":"Arthritis Rheum"},{"key":"1731_CR33","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","volume":"43","author":"EJ Kroot","year":"2000","unstructured":"Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL: The prognostic value of anti-cyclic citrullinated peptide antibodies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000, 43: 1831-1835. 10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6.","journal-title":"Arthritis Rheum"},{"key":"1731_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ard.62.2.120","volume":"62","author":"O Meyer","year":"2003","unstructured":"Meyer O, Labarre C, Dougados M, Goupilee P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B: Anti-citrullinated protein\/peptide antibody assay in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003, 62: 120-126. 10.1136\/ard.62.2.120.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/rheumatology\/keg184","volume":"42","author":"S Bas","year":"2003","unstructured":"Bas S, Genevay S, Metyer O, Gabay C: Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford). 2003, 42: 677-680. 10.1093\/rheumatology\/keg184.","journal-title":"Rheumatology (Oxford)"},{"key":"1731_CR36","first-page":"383","volume":"60","author":"WJ van Venrooij","year":"2002","unstructured":"van Venrooij WJ, Hazes JM, Visser H: Anticitrullinated protein\/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 2002, 60: 383-388.","journal-title":"Neth J Med"},{"key":"1731_CR37","unstructured":"Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT: The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis."},{"key":"1731_CR38","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/ard.2004.030262","volume":"64","author":"B Yazdani-Biuki","year":"2005","unstructured":"Yazdani-Biuki B, Standlmainer E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, Brickmann K, Graninger WB, Brezinschek HP: Blockade of tumor necrosis factor \u03b1 significantly alters the serum levels of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 1224-1226. 10.1136\/ard.2004.030262.","journal-title":"Ann Rheum Dis"},{"key":"1731_CR39","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1002\/art.20659","volume":"50","author":"TR Mikuls","year":"2004","unstructured":"Mikuls TR, O'Dell JR, Stoner JA, Parrish LA, Arend WP, Norris JM, Holers VM: Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004, 50: 3776-3782. 10.1002\/art.20659.","journal-title":"Arthritis Rheum"},{"key":"1731_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00003495-199039010-00003","volume":"39","author":"DE Furst","year":"1990","unstructured":"Furst DE: Rational use of disease-modifying antirheumatic drugs. Drugs. 1990, 39: 19-37.","journal-title":"Drugs"},{"key":"1731_CR41","doi-asserted-by":"crossref","first-page":"18119","DOI":"10.1016\/S0021-9258(19)84685-9","volume":"264","author":"M Inagaki","year":"1989","unstructured":"Inagaki M, Takahara H, Nishi Y, Sugawara K, Sato C: Ca2+-dependent deimination induced disassembly of intermediate filaments involves specific modification of the amino-terminal head domain. J Biol Chem. 1989, 264: 18119-18127.","journal-title":"J Biol Chem"},{"key":"1731_CR42","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/gast.2001.28702","volume":"121","author":"A Lugering","year":"2001","unstructured":"Lugering A, Schmidt M, Lugering N, Pauels HG, Domaschke W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001, 121: 1145-1157. 10.1053\/gast.2001.28702.","journal-title":"Gastroenterology"},{"key":"1731_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.rdc.2004.02.004","volume":"30","author":"E Keystone","year":"2004","unstructured":"Keystone E, Haraoui B: Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004, 30: 349-364. 10.1016\/j.rdc.2004.02.004.","journal-title":"Rheum Dis Clin North Am"},{"key":"1731_CR44","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/rheumatology\/26.5.346","volume":"26","author":"A Keane","year":"1987","unstructured":"Keane A, Woods R, Dowding V, Roden D, Barry C: Anticardiolipin antibodies in rheumatoid arthritis. Br J Rheumatol. 1987, 26: 346-350.","journal-title":"Br J Rheumatol"},{"key":"1731_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2133.1994.tb08456.x","volume":"131","author":"P Wolf","year":"1994","unstructured":"Wolf P, Gretler J, Aglas F, Auer-Grumbach P, Rainer F: Anticardiolipin antibodies in rheumatoid arthritis: their relation to rheumatoid nodules and cutaneous vascular manifestations. Br J Dermatol. 1994, 131: 48-51. 10.1111\/j.1365-2133.1994.tb08456.x.","journal-title":"Br J Dermatol"},{"key":"1731_CR46","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1073\/pnas.93.4.1624","volume":"93","author":"L Casciola-Rosen","year":"1996","unstructured":"Casciola-Rosen L, Rosen A, Petri M, Schlissel M: Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA. 1996, 93: 1624-1629. 10.1073\/pnas.93.4.1624.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1731_CR47","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.4049\/jimmunol.157.5.2201","volume":"157","author":"BE Price","year":"1996","unstructured":"Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, O'Laughlin T, Koh JS, Levine JS: Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol. 1996, 157: 2201-2208.","journal-title":"J Immunol"},{"key":"1731_CR48","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2796.2003.01298.x","volume":"255","author":"F D'Auria","year":"2004","unstructured":"D'Auria F, Rovere-Querini P, Giazzon M, Ajello P, Baldissera E, Manfredi AA, Sabbadini MG: Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med. 2004, 255: 409-418. 10.1111\/j.1365-2796.2003.01298.x.","journal-title":"J Intern Med"},{"key":"1731_CR49","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","volume":"167","author":"CS Via","year":"2001","unstructured":"Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD: In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001, 167: 6821-6826.","journal-title":"J Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1851.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar1851\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1851.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:26:02Z","timestamp":1728383162000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar1851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,9]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2005,2]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1186\/ar1851","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,9]]},"assertion":[{"value":"15 May 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R3"}}